Baidu Biomap, the Chinese biocomputing platform enterprise, has just completed a round of financing of 100 million US dollars, led by GGV capital. Robin Li, the founder of Baidu, continues to invest more. This round of financing will be mainly used for technology R & D and talent introduction. After this round of financing, the company will further strengthen the construction of its biological computing engine, continue research and development in the fields of multi-omics technology, high-throughput experimental technology, protein computing technology, and high-performance biological computing technology, strengthen the introduction of talents, and promote its first batch of drug R & D pipelines to a new stage.
Editor in Chief of FirmKnow.
China Concepts Stocks, A New Round of Return in 2021
January 17, 2021
BioMap, the Life Science Layout of Baidu
December 10, 2020
The largest financing in China’s biotechnology field, Everest Medicines has obtained $310 million in financing
December 1, 2020
The world’s major manufacturers of hyaluronic acid products
November 29, 2020